Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.

Bence C, Hofman V, Chamorey E, Long-Mira E, Lassalle S, Albertini AF, Liolios I, Zahaf K, Picard A, Montaudié H, Lacour JP, Passeron T, Andea AA, Ilie M, Hofman P.

J Eur Acad Dermatol Venereol. 2019 Oct 18. doi: 10.1111/jdv.16016. [Epub ahead of print]

PMID:
31625630
2.

Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).

Heeke S, Benzaquen J, Hofman V, Ilié M, Allegra M, Long-Mira E, Lassalle S, Tanga V, Salacroup C, Bonnetaud C, Fayada J, Gazoppi L, Ribeyre L, Castelnau O, Garnier G, Cattet F, Nanni I, de Fraipont F, Cohen C, Berthet JP, Leroy S, Poudenx M, Marquette CH, Denis MG, Barlesi F, Hofman P.

Clin Lung Cancer. 2020 Jan;21(1):56-65.e8. doi: 10.1016/j.cllc.2019.07.010. Epub 2019 Aug 3.

PMID:
31519454
3.

In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.

Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, Montaudié H, Dugourd PM, Chassang M, Passeron T, Delingette H, Marquette CH, Hofman V, Stenzinger A, Ilié M, Hofman P.

Cancers (Basel). 2019 Aug 29;11(9). pii: E1271. doi: 10.3390/cancers11091271.

4.

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.

Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud JM, Yguel C, Mazières J, Lepage AL, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette CH, Sabourin JC, Ilié M, Hofman P.

J Thorac Oncol. 2019 Jul;14(7):1204-1212. doi: 10.1016/j.jtho.2019.03.024. Epub 2019 Apr 15.

PMID:
30999109
5.

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time?

Hofman P, Badoual C, Henderson F, Berland L, Hamila M, Long-Mira E, Lassalle S, Roussel H, Hofman V, Tartour E, Ilié M.

Cancers (Basel). 2019 Feb 27;11(3). pii: E283. doi: 10.3390/cancers11030283. Review.

6.

Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.

Berland L, Heeke S, Humbert O, Macocco A, Long-Mira E, Lassalle S, Lespinet-Fabre V, Lalvée S, Bordone O, Cohen C, Leroy S, Hofman V, Hofman P, Ilié M.

J Thorac Dis. 2019 Jan;11(Suppl 1):S71-S80. doi: 10.21037/jtd.2018.11.102. Review.

7.

[The age of artificial intelligence in lung cancer pathology: Between hope, gloom and perspectives].

Heeke S, Delingette H, Fanjat Y, Long-Mira E, Lassalle S, Hofman V, Benzaquen J, Marquette CH, Hofman P, Ilié M.

Ann Pathol. 2019 Apr;39(2):130-136. doi: 10.1016/j.annpat.2019.01.003. Epub 2019 Feb 13. Review. French.

PMID:
30772062
8.

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients.

Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudié H, Tanga V, Allégra M, Lespinet-Fabre V, Bordone O, Bonnetaud C, Schiappa R, Butori C, Bence C, Lacour JP, Hofman V, Hofman P.

Oncotarget. 2018 Nov 16;9(90):36238-36249. doi: 10.18632/oncotarget.26343. eCollection 2018 Nov 16.

9.

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.

Ilié M, Ngo-Mai M, Long-Mira E, Lassalle S, Butori C, Bence C, Hamila M, Hofman V, Hofman P.

J Vis Exp. 2018 Sep 25;(139). doi: 10.3791/58082.

PMID:
30320751
10.

Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma.

Ilié M, Beaulande M, Ben Hadj S, Chamorey E, Schiappa R, Long-Mira E, Lassalle S, Butori C, Cohen C, Leroy S, Guérin O, Mouroux J, Marquette CH, Pomerol JF, Erb G, Hofman V, Hofman P.

Cancers (Basel). 2018 Sep 13;10(9). pii: E326. doi: 10.3390/cancers10090326.

11.

Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Washetine K, Heeke S, Bonnetaud C, Kara-Borni M, Ilié M, Lassalle S, Butori C, Long-Mira E, Marquette CH, Cohen C, Mouroux J, Selva E, Tanga V, Bence C, Félix JM, Gazoppi L, Skhiri T, Gormally E, Boucher P, Clément B, Dagher G, Hofman V, Hofman P.

Cancers (Basel). 2018 Jun 29;10(7). pii: E220. doi: 10.3390/cancers10070220.

12.

[Carcinoma of unknown primary. Case no. 5].

Long-Mira E.

Ann Pathol. 2018 Jun;38(3):185-187. doi: 10.1016/j.annpat.2018.04.014. Epub 2018 Jun 19. Review. French. No abstract available.

PMID:
29929746
13.

[Carcinoma of unknown primary. Case no. 6].

Long-Mira E.

Ann Pathol. 2018 Jun;38(3):188-190. doi: 10.1016/j.annpat.2018.04.015. Epub 2018 Jun 19. Review. French. No abstract available.

PMID:
29929745
14.

[Carcinoma of unknown primary. Role of the pathologist in 2018: Introduction].

Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M.

Ann Pathol. 2018 Jun;38(3):164-197. doi: 10.1016/j.annpat.2018.04.008. Epub 2018 Jun 19. French. No abstract available.

PMID:
29929740
15.

Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA.

Washetine K, Kara-Borni M, Heeke S, Bonnetaud C, Félix JM, Ribeyre L, Bence C, Ilié M, Bordone O, Pedro M, Maitre P, Tanga V, Gormally E, Mossuz P, Lorimier P, Marquette CH, Mouroux J, Cohen C, Lassalle S, Long-Mira E, Clément B, Dagher G, Hofman V, Hofman P.

Cancers (Basel). 2018 Jun 11;10(6). pii: E195. doi: 10.3390/cancers10060195.

16.

Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site.

Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M.

Cancers (Basel). 2018 Apr 5;10(4). pii: E108. doi: 10.3390/cancers10040108. Review.

17.

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.

Heeke S, Hofman V, Long-Mira E, Lespinet V, Lalvée S, Bordone O, Ribeyre C, Tanga V, Benzaquen J, Leroy S, Cohen C, Mouroux J, Marquette CH, Ilié M, Hofman P.

Cancers (Basel). 2018 Mar 21;10(4). pii: E88. doi: 10.3390/cancers10040088.

18.

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Hofman V, Lassalle S, Bence C, Long-Mira E, Nahon-Estève S, Heeke S, Lespinet-Fabre V, Butori C, Ilié M, Hofman P.

Cancers (Basel). 2018 Mar 13;10(3). pii: E70. doi: 10.3390/cancers10030070. Review.

19.

Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer.

Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin JC, Tanga V, Washetine K, Long-Mira E, Maitre P, Yazbeck N, Bordone O, Lespinet V, Leroy S, Cohen C, Mouroux J, Marquette CH, Hofman V, Hofman P.

Oncotarget. 2017 Oct 4;8(61):103055-103062. doi: 10.18632/oncotarget.21476. eCollection 2017 Nov 28.

20.

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients.

Ilie M, Szafer-Glusman E, Hofman V, Long-Mira E, Suttmann R, Darbonne W, Butori C, Lalvée S, Fayada J, Selva E, Yu W, Marquette CH, Shames DS, Punnoose E, Hofman P.

Oncotarget. 2017 Apr 18;8(16):26112-26121. doi: 10.18632/oncotarget.15345.

Supplemental Content

Loading ...
Support Center